Roivant Reports Positive Phase 3 CLARITY Results for Brepocitinib
Roivant said brepocitinib met the primary and all key secondary endpoints in the Phase 3 CLARITY trial in non-infectious uveitis.
Roivant announced positive Phase 3 CLARITY results showing brepocitinib met primary and all key secondary endpoints in non-infectious uveitis.Key Highlights:Original SEC Filing: Roivant Sciences Ltd. [ ROIV ] - 8-K - Oct. 21, 2026This is an AI-powered summary. It may contain inaccuracies.
Consider…